Yumeng Mao is a Senior Scientist at AstraZeneca in Cambridge, UK who is interested in the development of small molecule drugs that potentiate anti-tumour immunity. Yumeng started his training in tumour immunology in 2009 with Dr. Karl-Erik Hellstrom at the University of Washington in Seattle, USA. Subsequently, he completed his doctoral and post-doctoral work at the Karolinska Institute in Stockholm, Sweden with Prof. Rolf Kiessling. His research is centred around the mechanistic understanding of myeloid cells with suppressive functions in cancer patients, and in exploring therapeutic targeting strategies in these cell types using in vivo and in vitro experimental models. He has also investigated the regulation of human natural killer (NK) cells in the tumour microenvironment. Yumeng's seminar should be of broad interest to those in SLS interested in immunology, cancer, drug discovery and cell signaling.
‘Immuno-Oncology: Looking beyond T lymphocytes’
Tuesday, February 27, 2018 - 10:00 to 11:00
CTIR Sir Kenneth and Lady Noreen Murray Seminar Room
Professor Sir Philip Cohen FRS FRSE FAA FFMedSci
Dr Yumeng Mao
AstraZeneca, Cambridge, UK